 SAN DIEGO and TORONTO, July 19, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update. 